SLGL PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

SLGL ▼ -5.02% at T+5d

NEUTRAL call ✗ call lost -5.02% · α vs SPY -4.97% · entry $75.28 → $71.50

Next anchor: T+20d in 16d

Last close $80.00 (close Jun 8) · +6.27% from $75.28 entry

Entry anchored
May 27, 03:59 PM ET
via Databento tick

T+1d

-1.89%

call -1.89% · α -2.13%

$73.86

settled 12d ago

T+5d

-5.02%

call -5.02% · α -4.97%

$71.50

settled 6d ago

T+20d

—

call — · α —

—

in 16d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Sol-Gel reported Q1 2026 EPS of -$1.31, a 62.6% beat vs consensus of -$2.86, but revenue fell 90% YoY to $0.1M due to a prior-year milestone payment. The company raised $33.1M in an oversubscribed offering, received a patent allowance for SGT-610 extending protection to 2044, and signed an India license for TWYNEO. The Phase 3 readout for SGT-610 in Gorlin syndrome remains on track for Q4 2026.

Actionable Insight

The EPS beat is largely mechanical (lower R&D spend) and revenue collapsed, but the patent extension and capital raise de-risk the Phase 3 catalyst in Q4 2026. Monitor for top-line results; the stock may trade on pipeline milestones rather than quarterly financials.

Key Facts

Q1 2026 EPS -$1.31 vs consensus -$2.86 (62.6% beat)
Q1 2026 revenue $0.1M vs $1.0M YoY (down 90%)
Raised $33.1M gross in March 2026 underwritten offering
U.S. patent allowance for topical patidegib (SGT-610) extends protection to 2044
Phase 3 SGT-610 top-line results expected Q4 2026
Exclusive license agreement with Sun Pharma for TWYNEO in India
Cash and marketable securities $52.8M as of March 31, 2026; runway into Q1 2028
Net loss $3.7M vs $8.8M YoY (improved on lower R&D spend)

Financial Impact

EPS beat of 62.6% on a -$2.86 consensus; revenue decline of 90% YoY to $0.1M; $33.1M capital raise; cash position $52.8M

epsrevenuecashdilution

Risk Factors

Phase 3 SGT-610 trial failure or delay beyond Q4 2026
Dilution from $33.1M offering (shares outstanding increased ~17% from Dec 2025)
Revenue decline reflects non-recurring milestone; no recurring revenue base
Pre-commercialization stage; no approved product revenue from SGT-610

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3302777

4 reports for SLGL

T+1T+5T+20T+60

Filters

Reports for SLGL — sortable, filterable
	Type				Now
May 28, 2026 12d ago	6-K MIXED ★ 6/10	$75.28 $71.50	▼ −5.02%	▼ −4.97%	$80.00 (+6.27%)
May 28, 2026 12d ago	Press Release MIXED ★ 6/10	$75.28 $71.50	▼ −5.02%	▼ −4.97%	$80.00 (+6.27%)
Mar 24, 2026 11w ago	EFFECT NEUTRAL ★ 4/10	$80.01 $79.22	▼ −0.99%	▼ −0.56%	$80.00 (−0.01%)
Mar 19, 2026 11w ago	Press Release NEUTRAL ★ 4/10	$81.71 $77.75	▼ −4.85%	▼ −2.63%	$80.00 (−2.09%)

US Market Status

Market Closed — Opens in 6h 52m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access